Real-world clinical characteristics and treatment (tx) outcomes by co-mutation status in patients (pts) with <i>KRAS G12C</i>- mutated non-small cell lung cancer (NSCLC)

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPNEGRAO, Marcelo V.WU, Wen-HsingLINDSAY, Colin R.CAPARICA, RafaelPRETRE, VincentKANG, YehrimCARO, NydiaFARAGO, AnnaYE, FenCASTRO JR., Gilberto de2024-03-082024-03-082023CANCER RESEARCH, v.83, n.7, suppl.S, 20230008-5472https://observatorio.fm.usp.br/handle/OPI/58522engrestrictedAccessReal-world clinical characteristics and treatment (tx) outcomes by co-mutation status in patients (pts) with <i>KRAS G12C</i>- mutated non-small cell lung cancer (NSCLC)conferenceObjectCopyright AMER ASSOC CANCER RESEARCH10.1158/1538-7445.AM2023-918Oncology1538-7445